Welcome to our dedicated page for Nuvectis Pharma SEC filings (Ticker: NVCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuvectis Pharma, Inc. filings document the regulatory disclosures of a Nasdaq-listed clinical-stage oncology drug developer with common stock registered under the Exchange Act. Recent Form 8-K reports furnish quarterly and annual financial results, corporate updates, and exhibit press releases describing development activity for NXP900 and related operating progress.
Proxy materials cover annual meeting matters, director elections, auditor ratification, board composition, and stockholder voting procedures. Other material-event filings record governance changes such as director appointments, while cover-page disclosures identify Nuvectis as an emerging growth company and list its common stock trading on the Nasdaq Capital Market under NVCT.
Form 4 Overview: On 06/20/2025, Charles Mosseri-Marlio, a 10% owner of Nuvectis Pharma, Inc. (NVCT), filed a Form 4 disclosing an open-market purchase of 5,603 shares of the company’s common stock at a price of $7.99 per share. The transaction was executed indirectly through Emerald Hill Ventures SARL SPF, an entity Mosseri-Marlio beneficially owns.
Following the purchase, the insider’s aggregate ownership rose to 2,981,806 shares held indirectly and 109,321 shares held directly. The filing lists transaction code "P," signifying a standard open-market purchase. No sales, derivative security activity, or 10b5-1 plan indications were reported.
The additional shares represent less than 0.2% of Mosseri-Marlio’s total reported holdings but still reflect continued alignment with public shareholders. The filing contains no operational updates or financial metrics beyond the share purchase details.
Key take-away: Nuvectis Pharma, Inc. (NVCT) filed a Form 4 showing that 10% owner Charles Mosseri-Marlio, via Emerald Hill Ventures SARL SPF, bought 33,442 common shares in two open-market transactions on 17-18 Jun 2025.
- Prices: weighted-average $8.11 on 17 Jun for 5,399 shares and $8.05 (range $7.91-$8.11) on 18 Jun for 28,043 shares.
- Post-purchase holdings: 2,976,203 shares held indirectly, up from 2,942,761.
- Transaction code “P” confirms open-market purchases; no 10b5-1 plan indicated.
- No derivative securities or sales reported; filing does not include earnings or operational metrics.
The estimated cash outlay is roughly $270k; insider accumulation at market prices often signals management’s confidence and can be viewed as a bullish indicator by investors. Because the investor already owns more than 10% of NVCT, the additional purchase marginally increases an already significant stake and reinforces alignment with minority shareholders.